Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1

Fürst, Daniel E.; Keystone, Edward; So, Alexander; Braun, Jürgen; Breedveld, F C; Burmester, Gerd R; Benedetti, Fabrizio; Dörner, Thomas; Emery, Paul; Fleischmann, Roy; Gibofsky, Allan; Kalden, Joachim R.; Kavanaugh, Arthur; Kirkham, Bruce; Mease, Philip J.; Rubbert-Roth, Andrea; Sieper, Joachim; Singer, Nora G.; Smolen, Josef S; Riel, P.L.C.M. van; Weisman, Michael H.; Winthrop, Kevin

doi:10.1136/annrheumdis-2013-203348

Cited by 119 publications

(44 citation statements)

References 316 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, both the ACR2 and an expert group in an updated consensus statement on the use of biologic agents in rheumatic patients,1 have recommended repeat TB screening for patients receiving anti-TNF agents who have risk factors for TB and negative baseline screening with the TST or IGRAs. Furthermore, the ACR has recommended that re-screening should be performed annually 2.…”

Section: Discussionmentioning

confidence: 99%

“…Interferon-gamma (IFN-γ) release assays (IGRAs) including the T-SPOT.TB (Oxford Immunotec, Oxford, UK) and QuantiFERON-TB Gold In Tube (QFT-GIT; Cellestis, Carnegie, Victoria, Australia) assays are established tests for tuberculosis (TB) screening in rheumatic patients starting therapy with biologic agents, particularly anti-tumour necrosis factor (anti-TNF) 1 2. There is ongoing discussion whether IGRAs should be used alone, interchangeably or in combination with the traditional tuberculin skin test (TST) for TB screening in patients starting biologics, with most experts supporting a dual screening strategy regardless of the presence of TB risk factors 3 4…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Biological therapy represents an important advance in alleviating RA as a means of lessening symptoms, joint destruction and possibly lung disease in these patients 9 10. One therapeutic option has been the biological preparation, tumour necrosis factor (TNF) inhibitor, used despite the acknowledged risk of reactivating latent tuberculosis infection 11.…”

Section: Introductionmentioning

confidence: 99%

Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis

et al. 2014

View full text Add to dashboard Cite

ObjectivesBiological therapy represents important advances in alleviating rheumatoid arthritis (RA), but the effect on interstitial lung disease (ILD) has been controversial. The objective of this study was to assess the risk of such treatment for patients with ILD.DesignCase–control cohorts.SettingSingle centre in Japan.ParticipantsThis study included 163 patients with RA who underwent biological therapy.Outcome measuredWe assessed chest CT before initiation of biological therapy and grouped 163 patients according to the presence of ILD (with (n=58) and without pre-existing ILD (n=105)). Next, we evaluated serial changes of chest CT after treatment and visually assessed the emergence of ILD or its progression, which was referred to as an ‘ILD event’. Then, we also classified the patients according to the presence of ILD events and analysed their characteristics.ResultsTumour necrosis factor (TNF) inhibitors were administered to more patients with ILD events than those without ILD events (88% vs 60%, p<0.05), but recipients of tocilizumab or abatacept did not differ in this respect. Of 58 patients with pre-existing ILD, 14 had ILD events, and that proportion was greater than for those without pre-existing ILD (24% vs 3%, p<0.001). Of these 14 patients, all were treated with TNF inhibitors. Four patients developed generalised lung disease and two died from ILD progression. Baseline levels of KL-6 were similar in both groups, but increased in patients with ILD events.ConclusionsTNF inhibitors have the potential risk of ILD events, particularly for patients with pre-existing ILD, and KL-6 is a valuable surrogate marker for detecting ILD events. Our data suggest that non-TNF inhibitors are a better treatment option for these patients.

show abstract

“…В настоящее время большинство авторов, включая экс-пертов Европейской антиревматической лиги (EULAR), полагают, что у неактивных HBV-носителей терапия ГИБП может быть проведена при обязательном профилактиче-ском применении современных противовирусных препара-тов [99][100][101][102]. Выбор противовирусного препарата и дли-тельность его применения зависят от планируемой продол-жительности ГИБП-терапии и HBV-статуса, поэтому окон-чательное решение принимается только после консульта-ции гепатолога.…”

Section: пневмонияunclassified

Targeted Therapy and Infections in Rheumatic Diseases

Белов¹,

Наумцева²,

Тарасова³

et al. 2016

RJTAO

View full text Add to dashboard Cite

Ушедший в историю ХХ век ознаменовался беспреце-дентно активной борьбой с инфекционными заболевания-ми и принес целую серию блестящих открытий и достиже-ний в этой области. Однако в наступившем XXI веке инфек-ционные болезни по-прежнему сохраняют свою значимость как в медицинском, так и в социальном плане. Возрастаю-щее число вновь открываемых инфекционных болезней, возрождение ликвидированных нозологических форм, ус-тановление инфекционной природы ряда заболеваний -все это стало предметом повседневного внимания врачей различных специальностей, в том числе ревматологов.Несомненного внимания в современной ревматологии заслуживает проблема коморбидных инфекций (КИ), фор-мирование которых обусловлено как самим ревматическим заболеванием (РЗ), так и необходимостью применения пре-паратов с иммуносупрессивным действием. КИ оказывают значительное влияние на морбидность и летальность, осо-бенно при диффузных болезнях соединительной ткани. Данная проблема в последние годы стала еще более важной в связи с активным и все нарастающим внедрением в кли-ническую практику генно-инженерных биологических пре-паратов (ГИБП), действие которых направлено на специ-фические компоненты патогенеза РЗ. Применение ГИБП позволило достичь больших успехов, в первую очередь в ле-чении ревматоидного артрита (РА). Сегодня ГИБП включе-ны во все национальные и международные руководства по (TB, pneumonia, chronic viral hepatitis, herpesvirus infection, etc.)

show abstract

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1

Cited by 119 publications

References 316 publications

Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases

Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases

Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis

Targeted Therapy and Infections in Rheumatic Diseases

Contact Info

Product

Resources

About